CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Cergentis has developed Targeted Locus Amplification (TLA) technology for comprehensive genetic testing in cancer diagnostics. This platform aims to improve the detection of genetic variants, enhancing personalized treatment options for patients.
Next-generation sequencing (NGS)-based genetic tests are at the forefront of the adoption of personalized medicine in cancer.
However, current tests rely on the sequencing of short fragments covering only a fraction of the complete sequence of genes of interest.
By missing clinically relevant genetic variants, including structural changes such as gene fusions, genetic diagnostics for personalized medicine is suboptimal and ineffective.
There is therefore an unmet need for a cost-effective techno…
CERGENTIS BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
